Folinic acid
| |
| Folinic acid
| |
| Systematic (IUPAC) name | |
| 2-[4-[(2-amino-5-formyl-4-oxo-5,6,7,8- tetrahydro-1H-pteridin-6-yl)methylamino] benzoyl]aminopentanedioic acid | |
| Identifiers | |
| CAS number | |
| ATC code | V03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H23N7O7 |
| Mol. mass | 473.44 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Dose dependent:
|
| Protein binding | ~15% |
| Metabolism | ? |
| Half life | 6.2 hours |
| Excretion | Urinary |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Intravenous, oral |
|
WikiDoc Resources for Folinic acid | |
|
Articles | |
|---|---|
|
Most recent articles on Folinic acid Most cited articles on Folinic acid | |
|
Media | |
|
Powerpoint slides on Folinic acid | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Folinic acid at Clinical Trials.gov Clinical Trials on Folinic acid at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Folinic acid
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Folinic acid Discussion groups on Folinic acid Patient Handouts on Folinic acid Directions to Hospitals Treating Folinic acid Risk calculators and risk factors for Folinic acid
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Folinic acid | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Folinic acid (INN) or leucovorin (USAN), generally administered as calcium folinate (or leucovorin calcium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate. It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.
Folinic acid is not folic acid.
Mechanism of action
Folinic acid is a 5-formyl derivative of tetrahydrofolic acid. It is readily converted to other reduced folic acid derivatives (e.g. tetrahydrofolate), and thus has vitamin activity which is equivalent to folic acid. However, since it does not require the action of dihydrofolate reductase for its conversion, its function as a vitamin is unaffected by inhibition of this enzyme by drugs such as methotrexate.
Folinic acid, therefore, allows for some purine/pyrimidine synthesis to occur in the presence of dihydrofolate reductase inhibition, so that some normal DNA replication and RNA transcription processes can proceed.
Therapeutic use
Folinic acid is administered at the appropriate time following methotrexate as part of a total chemotherapeutic plan, where it may "rescue" bone marrow and gastrointestinal mucosa cells from methotrexate. There is no apparent effect on preexisting methotrexate-induced nephrotoxicity.[1]
While not specifically an antidote for methotrexate, folinic acid may also be useful in the treatment of acute methotrexate overdose. Different dosing protocols are used, but folinic acid should be re-dosed until the methotrexate level is less than 5 x 10-8 M (this can also be re-stated as < 0.05 μM) [2]
Folinic acid is also used in combination with the chemotherapy agent 5-fluorouracil in treating colon cancer. In this case, folinic acid is not used for "rescue" purposes; rather, it enhances the effect of 5-fluorouracil on inhibiting thymidylate synthase.
Folinic acid is also sometimes used to prevent toxic effects of high doses of antimicrobial dihydrofolate reductase inhibitors such as trimethoprim and pyrimethamine.
Note on administration
Folinic acid should not be administered intrathecally. This may produce severe adverse effects or even death.[3]
References
- ↑ Therapeutic Information Resources Australia (2004). Calcium Folinate (Systemic) in AUSDI: Australian Drug Information for the Health Care Professional. Castle Hill: Therapeutic Information Resources Australia.
- ↑ www.cancercare.on.ca/pdfdrugs/leucovo.pdf
- ↑ Jardine, LF et al (1996). "Intrathecal Leucovorin After Intrathecal Methotrexate Overdose". J Pediatr Hematol Oncol 18 (3): 302–304. PMID 8689347.
Detoxifying agents for antineoplastic treatment (V03AF) |
|---|
| Mesna - Dexrazoxane - Calcium folinate - Calcium levofolinate - Amifostine - Sodium folinate - Rasburicase - Palifermin |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
